Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

The MD Anderson Cancer Center (MDACC) Experience with Ruxolitinib, An Oral JAK1 and JAK2 Inhibitor, in Myelofibrosis: Long-Term Follow-up Outcomes of 107 Patients From a Phase I/II Study,

Srdan Verstovsek, MD, PhD, Zeev Estrov, Jorge E. Cortes, Deborah A. Thomas, MD, Gautam Borthakur, Tapan Kadia, Elias Jabbour, Sherry Pierce, RN, BS, Hagop M. Kantarjian

Blood (2011) 118 (21): 3851.

https://doi.org/10.1182/blood.V118.21.3851.3851

Published: 2011

Journal Articles

Incidence, Characteristics, and Outcome of FLT3-ITD Mutations in AML Arising from an Antecedent Hematologic Disorder

Tapan Kadia, Farhad Ravandi, MD, Gautam Borthakur, Elias Jabbour, Sherry Pierce, RN, BS, Guillermo Garcia-Manero, Stefan Faderl, MD, Jorge E. Cortes, Hagop M. Kantarjian

Blood (2011) 118 (21): 2522.

https://doi.org/10.1182/blood.V118.21.2522.2522

Published: 2011

Journal Articles

Comparison of Outcomes of Advanced Myelofibrosis Patients Treated with Ruxolitinib (INCB018424) to Those of a Historical Control Group: Survival Advantage of Ruxolitinib Therapy

Srdan Verstovsek, MD, PhD, Hagop M. Kantarjian, Zeev Estrov, Jorge E. Cortes, Deborah A. Thomas, MD, Tapan Kadia, Sherry Pierce, RN, BS, Mario Cazzola, Elisa Rumi, Enrica Morra, Ester Pungolino, Domenica Caramazza, Francesco Passamonti, MD

Blood (2011) 118 (21): 793.

https://doi.org/10.1182/blood.V118.21.793.793

Published: 2011

Journal Articles

A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia

Alfonso QuintÀs-Cardama, MD, Hawk Kim, MD, Jianqin Shan, PhD, Elias Jabbour, Stefan Faderl, MD, William G. Wierda, MD, PhD, Farhad Ravandi, MD, Tapan Kadia, Sa A. Wang, MD, Sherry Pierce, RN, BS, Hagop M Kantarjian, Guillermo Garcia-Manero

Blood (2011) 118 (21): 967.

https://doi.org/10.1182/blood.V118.21.967.967

Published: 2011

Journal Articles

Final Report of a Phase II Trial of Vorinostat with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Guillermo Garcia-Manero, Francesco Paolo Tambaro, MD, PhD, Nebiyou Bekele, Hui Yang, Farhad Ravandi, MD, Elias Jabbour, Gautam Borthakur, Tapan Kadia, Marina Konopleva, M.D., Ph.D., Stefan Faderl, MD, Jorge E. Cortes, Mark Brandt, BS, Yumin Hu, PhD, Deborah McCue, Willie Mae Newsome, RN, Sherry Pierce, RN, BS, Marcos DeLima, MD, Hagop M. Kantarjian

Blood (2011) 118 (21): 763.

https://doi.org/10.1182/blood.V118.21.763.763

Published: 2011

Journal Articles

Coagulation Profile As Prognostic Indicator in Acute Myeloid Leukemia,

Francisca C. Gushiken, MD, Yen Dai Vo, Lianchun Xiao, Tapan Kadia, Jorge E. Cortes, Naveen Pemmaraju, MD, Sherry Pierce, RN, BS, Hagop M. Kantarjian, MD, Gautam Borthakur

Blood (2011) 118 (21): 3593.

https://doi.org/10.1182/blood.V118.21.3593.3593

Published: 2011

Journal Articles

Impact of Npm1, Flt3, and Ras Mutations on the Outcomes of Elderly Patients with Acute Myeloid Leukemia,

Alfonso Quintás-Cardama, MD, Hagop M. Kantarjian, Guillermo Garcia-Manero, Farhad Ravandi, MD, Mark Brandt, BS, Sherry Pierce, RN, BS, Gautam Borthakur, Jorge E. Cortes

Blood (2011) 118 (21): 3594.

https://doi.org/10.1182/blood.V118.21.3594.3594

Published: 2011

Journal Articles

Activating Mutations of the FMS-Like Tyrosine Kinase-3 (FLT3) At Complete Response and Relapse in Patients with Acute Myeloid Leukemia,

Aziz Nazha, Jorge E. Cortes, Stefan Faderl, MD, Sherry Pierce, RN, BS, Guillermo Garcia-Manero, Susan O'Brien, MD, Alessandra Ferrajoli, MD, Tapan Kadia, Gautam Borthakur, Rajyalakshmi Luthra, PhD, Hagop M. Kantarjian, Farhad Ravandi, MD

Blood (2011) 118 (21): 3557.

https://doi.org/10.1182/blood.V118.21.3557.3557

Published: 2011

Journal Articles

Predictors of Outcome In Adult Patients with Acute Myeloid Leukemia In First Relapse,

Farhad Ravandi, MD, Stefan Faderl, MD, Sherry Pierce, RN, BS, Guillermo Garcia-Manero, Mark Brandt, BS, Jianqin Shan, PhD, Tapan Kadia, Gautam Borthakur, Zeev Estrov, Susan o'Brien, Jorge E. Cortes, Hagop M. Kantarjian

Blood (2011) 118 (21): 3569.

https://doi.org/10.1182/blood.V118.21.3569.3569

Published: 2011

Journal Articles

Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) or Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm,

Pamela S Becker, MD, PhD, Bruno C. Medeiros, MD, Frederick R. Appelbaum, MD, Bart Lee Scott, MD, Paul C. Hendrie, MD, PhD, Barry Storer, PhD, Sherry Pierce, RN, BS, Stephen H. Petersdorf, MD, Elihu H. Estey, MD

Blood (2011) 118 (21): 3617.

https://doi.org/10.1182/blood.V118.21.3617.3617

Published: 2011

Journal Articles

FLT3 Inhibitors Are Promising Salvage Therapy for Relapsed or Refractory Acute Myeloid Leukemia (AML) in Patients with FLT3-ITD Mutations,

Koichi Takahashi, MD, Hagop M. Kantarjian, Naveen Pemmaraju, MD, Gautam Borthakur, Stefan Faderl, MD, Guillermo Garcia-Manero, Michael Andreeff, M.D., Ph.D., Sherry Pierce, RN, BS, Farhad Ravandi, MD, Jorge E. Cortes

Blood (2011) 118 (21): 3623.

https://doi.org/10.1182/blood.V118.21.3623.3623

Published: 2011

Journal Articles

Outcomes of Patients (pts) with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated with Hyper-CVAD-Based Chemotherapy Regimens: MD Anderson Case Series

Naveen Pemmaraju, MD, Deborah A. Thomas, MD, Hagop M. Kantarjian, Sherry Pierce, RN, BS, Susan O’Brien, MD, Jorge E. Cortes, Stefan Faderl, MD

Blood (2011) 118 (21): 4263.

https://doi.org/10.1182/blood.V118.21.4263.4263

Published: 2011

Journal Articles

Clinical Significance of Bone Marrow Fibrosis in Patients with Polycythemia Vera

Aziz Nazha, Jorge E. Cortes, Zeev Estrov, Sherry Pierce, RN, BS, Hagop M. Kantarjian, Srdan Verstovsek, MD, PhD

Blood (2011) 118 (21): 5149.

https://doi.org/10.1182/blood.V118.21.5149.5149

Published: 2011

Journal Articles

Patients' Comorbidities and Overall Survival in Primary Myelofibrosis (PMF)

Kiran Naqvi, MD, Maria Tanaka, MD, Guillermo Garcia-Manero, Sherry Pierce, RN, BS, Hagop M. Kantarjian, Srdan Verstovsek, MD, PhD

Blood (2011) 118 (21): 5164.

https://doi.org/10.1182/blood.V118.21.5164.5164

Published: 2011

Journal Articles

Dynamic Prognostic Model to Identify Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Mf) At the Highest Risk of Death and Transformation to Acute Myeloid Leukemia

Alfonso Quintás-Cardama, MD, Jenny Shan, PhD, Sherry Pierce, RN, BS, Hagop M. Kantarjian, Srdan Verstovsek, MD, PhD

Blood (2011) 118 (21): 2821.

https://doi.org/10.1182/blood.V118.21.2821.2821

Published: 2011

Journal Articles

Prognostic Implications and Clinical Characteristics Associated with Bone Marrow Fibrosis in Patients with Myelofibrosis

Aziz Nazha, Zeev Estrov, Jorge E. Cortes, Sherry Pierce, RN, BS, Hagop M. Kantarjian, Srdan Verstovsek, MD, PhD

Blood (2011) 118 (21): 2824.

https://doi.org/10.1182/blood.V118.21.2824.2824

Published: 2011

Journal Articles

ROS Activation Independent From Iron Overload in MDS

Francesco Paolo Tambaro, MD, PhD, William G. Wierda, MD, PhD, Sherry Pierce, RN, BS, Hui Yang, MD, PhD, Yue Wei, PhD, Zhihong Fang, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero

Blood (2011) 118 (21): 2798.

https://doi.org/10.1182/blood.V118.21.2798.2798

Published: 2011

Journal Articles

Impact of Combining Targeted Agents with High-Dose Cytarabine-Based Induction Chemotherapy on Acute Myeloid Leukemia Outcomes: The M.D. Anderson Cancer Center Experience

Alfonso Quintás-Cardama, MD, Hagop M. Kantarjian, Guillermo Garcia-Manero, Mark Brandt, BS, Stefan Faderl, MD, Sherry Pierce, RN, BS, Gautam Borthakur, Farhad Ravandi, MD, Jorge E. Cortes

Blood (2011) 118 (21): 1539.

https://doi.org/10.1182/blood.V118.21.1539.1539

Published: 2011

Journal Articles

Impact of Epigenetic Therapy Versus Conventional Chemotherapy on Survival of Elderly Patients with Acute Myeloid Leukemia

Alfonso Quintás-Cardama, MD, Hagop M Kantarjian, Guillermo Garcia-Manero, Farhad Ravandi, MD, Mark Brandt, BS, Stefan Faderl, MD, Sherry Pierce, RN, BS, Gautam Borthakur, Jorge E. Cortes

Blood (2011) 118 (21): 1494.

https://doi.org/10.1182/blood.V118.21.1494.1494

Published: 2011

Journal Articles

Validating the Lower-Risk MD Anderson Prognostic Scoring System (LR-PSS) and the Revised International Prognostic Scoring System (IPSS-R) for Patients with Myelodysplastic Syndromes

Mikkael A. Sekeres, MD, MS, Paul Elson, Ramon V. Tiu, MD, Yogen Saunthararajah, MD, Anjali S. Advani, MD, Katarina Paulic, Josephine Chan, Sherry Pierce, RN, BS, Elias Jabbour, Hagop M. Kantarjian, Jaroslaw P. Maciejewski, MD, PhD, Guillermo Garcia-Manero

Blood (2011) 118 (21): 1720.

https://doi.org/10.1182/blood.V118.21.1720.1720

Published: 2011

NARROW

The MD Anderson Cancer Center (MDACC) Experience with Ruxolitinib, An Oral JAK1 and JAK2 Inhibitor, in Myelofibrosis: Long-Term Follow-up Outcomes of 107 Patients From a Phase I/II Study,

Incidence, Characteristics, and Outcome of FLT3-ITD Mutations in AML Arising from an Antecedent Hematologic Disorder

Comparison of Outcomes of Advanced Myelofibrosis Patients Treated with Ruxolitinib (INCB018424) to Those of a Historical Control Group: Survival Advantage of Ruxolitinib Therapy

A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia

Final Report of a Phase II Trial of Vorinostat with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Coagulation Profile As Prognostic Indicator in Acute Myeloid Leukemia,

Impact of Npm1, Flt3, and Ras Mutations on the Outcomes of Elderly Patients with Acute Myeloid Leukemia,

Activating Mutations of the FMS-Like Tyrosine Kinase-3 (FLT3) At Complete Response and Relapse in Patients with Acute Myeloid Leukemia,

Predictors of Outcome In Adult Patients with Acute Myeloid Leukemia In First Relapse,

Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) or Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm,

FLT3 Inhibitors Are Promising Salvage Therapy for Relapsed or Refractory Acute Myeloid Leukemia (AML) in Patients with FLT3-ITD Mutations,

Outcomes of Patients (pts) with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated with Hyper-CVAD-Based Chemotherapy Regimens: MD Anderson Case Series

Clinical Significance of Bone Marrow Fibrosis in Patients with Polycythemia Vera

Patients' Comorbidities and Overall Survival in Primary Myelofibrosis (PMF)

Dynamic Prognostic Model to Identify Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Mf) At the Highest Risk of Death and Transformation to Acute Myeloid Leukemia

Prognostic Implications and Clinical Characteristics Associated with Bone Marrow Fibrosis in Patients with Myelofibrosis

ROS Activation Independent From Iron Overload in MDS

Impact of Combining Targeted Agents with High-Dose Cytarabine-Based Induction Chemotherapy on Acute Myeloid Leukemia Outcomes: The M.D. Anderson Cancer Center Experience

Impact of Epigenetic Therapy Versus Conventional Chemotherapy on Survival of Elderly Patients with Acute Myeloid Leukemia

Validating the Lower-Risk MD Anderson Prognostic Scoring System (LR-PSS) and the Revised International Prognostic Scoring System (IPSS-R) for Patients with Myelodysplastic Syndromes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only